RAPT Therapeutics Inc. (RAPT) Financial Statements (2024 and earlier)

Company Profile

Business Address 561 ECCLES AVENUE
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:158,900249,100189,700111,50077,383
Cash and cash equivalents47,47838,94624,02724,91877,383
Short-term investments111,384210,122165,62786,592 
Other undisclosed cash, cash equivalents, and short-term investments383246(10) 
Other undisclosed current assets2,8823,5943,2734,0983,123
Total current assets:161,782252,694192,973115,59880,506
Noncurrent Assets
Operating lease, right-of-use asset5,2286,940   
Property, plant and equipment2,4482,5392,7412,9823,707
Other noncurrent assets3,8714,0362,922389389
Total noncurrent assets:11,54713,5155,6633,3714,096
TOTAL ASSETS:173,329266,209198,636118,96984,602
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities19,27912,0218,3257,3184,785
Accounts payable5,1763,3651,9992,3831,143
Accrued liabilities14,1038,6566,3264,9353,642
Deferred revenue   1,0164,0964,000
Other liabilities10932254328471
Other undisclosed current liabilities2,4482,171   
Total current liabilities:21,83614,2249,59511,7429,256
Noncurrent Liabilities
Liabilities, other than long-term debt4,4586,8192,6613,0482,225
Deferred revenue   511863 
Deferred rent credit   2,1502,1852,225
Operating lease, liability4,4586,819   
Total noncurrent liabilities:4,4586,8192,6613,0482,225
Total liabilities:26,29421,04312,25614,79011,481
Equity
Equity, attributable to parent147,035245,166186,380104,17973,121
Common stock33322
Additional paid in capital631,611613,073470,629319,196235,049
Accumulated other comprehensive income (loss)103(26)(206)(177)20
Accumulated deficit(484,682)(367,884)(284,046)(214,842)(161,950)
Total equity:147,035245,166186,380104,17973,121
TOTAL LIABILITIES AND EQUITY:173,329266,209198,636118,96984,602

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues  1,5273,8135,042 
Gross profit:  1,5273,8135,042 
Operating expenses(127,062)(87,322)(73,022)(58,256)(43,629)
Operating loss:(127,062)(85,795)(69,209)(53,214)(43,629)
Nonoperating income10,2641,95751,3121,292
Investment income, nonoperating   (1,270)(497) 
Gain (loss), foreign currency transaction, before tax 655(627)(258)249(24)
Loss from continuing operations before income taxes:(116,798)(83,838)(69,204)(51,902)(42,337)
Income tax expense    (990)(660)
Loss from continuing operations:(116,798)(83,838)(69,204)(52,892)(42,997)
Loss before gain (loss) on sale of properties:(69,204)(52,892)(42,997)
Net loss available to common stockholders, diluted:(116,798)(83,838)(69,204)(52,892)(42,997)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(116,798)(83,838)(69,204)(52,892)(42,997)
Comprehensive loss:(116,798)(83,838)(69,204)(52,892)(42,997)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent129180(29)(197)24
Comprehensive loss, net of tax, attributable to parent:(116,669)(83,658)(69,233)(53,089)(42,973)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: